The Valley Desk

NCT05303519 · Interventional trial

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

Overall registry status Recruiting

Phase 3

Conditions Astrocytoma, Grade IV, Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Glioma, IDH1-mutant Glioma, Oligodendroglioma, Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov